Vascular dementia Trials in Disease

Study on the Benefits of Amyloid PET Imaging with Florbetaben (18F) and Flutemetamol (18F) for Patients with Various Types of Dementia

This clinical trial is investigating whether a special type of brain scan called amyloid PET imaging can provide better information for diagnosing and managing patients with different types of dementia, including vascular dementia. The study compares this advanced imaging technique with standard diagnostic procedures to see if it improves understanding and treatment planning.

Main inclusion criteria: Patients eligible for this trial must be at least 50 years old and have mild to moderate dementia with unclear or uncertain diagnosis. They should have a Clinical Dementia Rating Scale score between 0.5 and 3.0, and a Mini-Mental-Status Test score greater than 10. Valid German compulsory health insurance is required, and participants need someone who can provide information about them, such as a family member or friend. The diagnosis of dementia must be uncertain (less than 85% certainty), or standard CSF testing must be unavailable or inconclusive. Participants must be willing to undergo amyloid PET imaging and agree to know the results if selected for that part of the study.

Main exclusion criteria: The trial cannot include patients with certain specific types of dementia or associated conditions. This includes Parkinson's disease with dementia, Alzheimer's disease (both early and late onset), vascular dementia, HIV-related dementia, Pick's disease, Huntington's disease with dementia, and Creutzfeldt-Jakob disease with dementia.

Main focus and goal: The primary goal is to determine whether amyloid PET imaging provides better diagnostic information compared to standard methods. The study examines how this imaging affects the management of daily activities and overall quality of life for people with dementia. Participants are randomly assigned to either receive the amyloid PET imaging or standard diagnostic procedures. Those who receive the imaging will have an intravenous injection of either Neuraceq or VIZAMYL solution, which contains substances that help highlight certain areas of the brain during the scan. Follow-up assessments occur at 26, 52, 78, and 104 weeks to measure changes in cognitive performance, quality of life, and care needs.

Investigational approach: The trial uses amyloid PET imaging as the diagnostic tool being studied. This technique involves a brain scan that uses radioactive tracers (florbetaben or flutemetamol) to detect amyloid plaques in the brain, which are protein deposits associated with Alzheimer's disease and other forms of dementia. The imaging helps doctors see these plaques more clearly, potentially leading to more accurate diagnoses and better treatment planning.

Summary

Currently, there is only one ongoing clinical trial specifically addressing vascular dementia and related conditions. This trial is being conducted in Germany and focuses on evaluating advanced diagnostic imaging techniques rather than testing new treatments. The study aims to determine whether amyloid PET imaging can improve the accuracy of dementia diagnosis and enhance patient care management compared to standard diagnostic methods. While the trial excludes patients with certain specific types of dementia, it includes those with unclear or uncertain diagnoses, which is common in clinical practice. The use of imaging agents like florbetaben and flutemetamol represents a diagnostic approach rather than a therapeutic intervention, highlighting the current research focus on improving diagnostic accuracy in dementia care.